Chrome Extension
WeChat Mini Program
Use on ChatGLM
VIPCreated with Sketch.

MM-328 Efficacy and Safety of Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma (RRMM) with High-Risk (HR) Features: a Subgroup Analysis from the Phase 1/2 MajesTEC-1 Study

Luciano J Costa,Nizar J Bahlis,Saad Z Usmani,Niels WCJ van de Donk, Ajay K Nooka, Aurore Perrot,Keqin Qi,Caroline Hodin,Clarissa Uhlar,Athena Zuppa,Katherine Chastain, Margaret Doyle,María-Victoria Mateos

Clinical Lymphoma Myeloma and Leukemia（2024）

Cited 0|Views1
Key words
MM,relapsed/refractory multiple myeloma,bispecific antibody,high-risk,phase1/2
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined